IVI in the Media

EIU Perspectives | What does Denmark’s permanent suspension of both the AstraZeneca and Janssen covid-19 vaccines mean for other countries?

Asia Times | Vaccinations in a race against viral variants

Nature | Why COVID vaccines are so difficult to compare

DEVEX | Opinion: COVAX — too big, and too important, to fail

CNN | “Our response needs to be clear, strong, and unified”

South China Morning Post | Coronavirus vaccines will save 2021? Not so fast, here’s what the experts think

Bloomberg | Will the Covid-19 Vaccines Be Effective and Safe?

Asian Boss | Update On COVID-19 Vaccine Price & Schedule From A Leading Vaccine Expert

The Telegraph | ‘If you are not prepared, the virus has found every weakness’: How countries in Asia tamed Covid-19

CGTN | ‘The vaccine itself is not the silver bullet,’ says International Vaccine Institute

Devex | Q&A: Why Jerome Kim is ‘hopeful’ but cautious about distributing a COVID-19 vaccine

Maeil Business Newspaper | IVI Director General Jerome Kim Shares His Thoughts on Resurgence of COVID-19 Outbreaks in S. Korea

Chosun Ilbo | IVI Director General Jerome Kim Shares His Thoughts on Equitable Access of COVID-19 Vaccines

Channel News Asia | On a fast track like never before: The COVID-19 vaccine effort and 5 vital questions

The Economist’s Future of Healthcare Insight Hour | Vaccine development: A race to the finish line

Devex | Q&A: Is COVID-19 helping or hindering progress toward an HIV vaccine?

TED | The trials, tribulations and timeline of a COVID-19 vaccine

Wired Korea | The End of World War C: Peace without Victory?

Asian Boss | World’s Leading Vaccine Expert Fact-Checks COVID-19 Vaccine Conspiracy

Development Today | Why Sweden funds a vaccine institute in Korea and not Oslo-based CEPI

CNBC | Parts of Asia that relaxed restrictions without a resurgence in coronavirus cases did these three things

The Korea Herald | [Herald Interview] ‘Making vaccines accessible is biggest COVID-19 challenge’

CGTN: The Agenda with Stephen Cole | Speed of vaccine trials is ‘unprecedented’

Asian Boss | We Asked The World’s Leading Vaccine Expert About COVID-19 Vaccine

The Guardian | Test, trace, contain: how South Korea flattened its coronavirus curve

BBC World Service: The Inquiry | How do we come out of the lockdown? (13:00)

ANC 24/7 | Int’l Vaccine Institute: 12-18 months reasonable timetable for development of Covid-19 vaccine

Seeker | How Fast Can We Make a Coronavirus Vaccine?

Education City Speaker Series: Flattening the Curve – Global Responses to COVID-19

Wion News | About 70% of vaccines used around the world are made in India: S Korean expert Dr Jerome Kim

South China Morning Post | How long will a coronavirus vaccine take? A Q&A with Jerome Kim, head of the International Vaccine Institute

BBC World News | Jerome Kim: Vaccines are the long-term solution to the pandemic

The Korea Times | Developing vaccine against COVID-19

TRT: Bigger than Five | COVID-19: The World Reacts

South Korea’s fight against coronavirus (CBS News)

NDTV | Top South Korea Doctor On Why He Thinks Coronavirus Is Not A ‘Chinese Virus’

RTE | What South Korea can teach Ireland about fighting Covid-19

Physical distancing should last months, not weeks, says epidemiologist (Yahoo News Canada)

Development of vaccine requires massive investment… international cooperation is needed (Korea Economic Daily)

COVID-19 Pandemic (Arirang TV, 22:50~46:00)

By then, we’ll have a vaccine on our side (Hankyoreh—Korean)

Coronavirus Pandemic: International Vaccine Institute director on how long it will take to develop vaccine (CGTN)

Testing times: Why South Korea’s COVID-19 strategy is working (Al Jazeera English)

Genexine seeks to compress the vaccine timeline

Genexine, Binex to develop COVID-19 vaccine (Korea Biomedical Review)

Genexine, Binex to co-develop coronavirus vaccine GX-19 (Korea Herald)

How close are we to a COVID-19 vaccine? Jerome H. Kim from International Vaccine Institute (Arirang News)

COVID-19 vaccine, drugs on fast track for development: IVI chief (Yonhap News)

Inside the race to find a coronavirus vaccine (Devex)

Chinese students keen for turnaround (China Daily)

China Daily | S. Korea can try out makeshift hospitals, experts say

Director General Jerome Kim for Phoenix TV

Speed and accuracy vital for COVID-19 test kits (Arirang News)

2020 COVID-19 Live Updates: Jerome Kim for tbs eFM

Jerome Kim for KBS WORLD Radio, Korea24 on the COVID-19 outbreak in South Korea

Korea should join efforts in vaccine development to prevent pandemics (JoongAng Ilbo)

Future global health threats

IVI: COVID-19 could linger (Korean)

Jerome Kim for Korea, Factual: “Hong Kong’s handling of COVID-19 outbreak & Prospects of vaccine development”

Concerns about the spread of COVID-19: When will a vaccine be developed? When can we expect the “Super Vaccine”?

Al Jazeera English | Scientists call for global cooperation over coronavirus

When will COVID-19 vaccine be commercialized…And “super vaccine”? (Korean)

Global push to find vaccine against devastating bug growing

IVI receives $15.7 million to conduct Ph III trials of typhoid vaccine

Korean vaccines expanding global territory

Neglected Victims of Neglected Diseases

Let’s build a common defense against epidemics

Vaccine investment brings 16-fold return… partnering with Bill Gates

World must join forces to prevent infectious diseases

IVI editorial in The Korea Herald advocates for Korean leadership for global health

×

IVI’s Advanced Vaccinology Course Marks 15th Annual Event

Author
Margaret
Date
2015-05-12 00:00
Views
2269

 

IVI’s Advanced Vaccinology Course Marks 15th Annual Event

 

Dr. Jerome Kim, Director General of the International Vaccine Institute, delivers welcome remarks at the opening session of the 15th IVI International Advanced Course in the Asia-Pacific Region at IVI headquarters in Seoul on Monday.

 

  •  

    • Course has trained about 1,000 healthcare professionals and policymakers from over 30 nations in the vaccine sciences

    • Nearly 140 participants from 29 countries including trainees participate in this year’s course, which runs from May 11-15 at IVI headquarters

    • IVI Director General Dr. Jerome Kim urges ‘increased developing country capacity in vaccine research, development, epidemiology, and immunization to ensure prompt responses to potential outbreaks as a result of emergency crises and natural disasters’

    • More than 30 experts from international agencies, research institutions, industry and non-profit organizations, including IVI, WHO and the U.S. NIH will serve as faculty members
  •  

 

May 11, 2015, Seoul, South Korea— The International Vaccine Institute (IVI), the first international organization hosted by the Republic of Korea, convenes the 15th Advanced Vaccinology Course (AVC) in the Asia-Pacific Region at IVI headquarters from May 11 to 15. The annual course aims to build capacity of health professionals and decision-makers, especially those from developing countries, in the entire vaccine continuum spanning vaccine development, evaluation, production and policy in order to help increase developing nations’ capacity in vaccine research and immunization.

 

This year’s AVC marks the 15th anniversary, as the highly subscribed course brings together nearly 140 participants from 29 countries, including trainees and faculty from Korea, the U.S., and India. Over the past 15 years, the course has trained about1,000 scientists, public health officials, and policymakers from the private and public sectors from over 30 countries worldwide. The trainees include participants from developing countries who are invited through fellowships funded by course sponsors that include KEB Foundation and Sky72 Golf Club. Many of the past participants have become leaders in vaccines and immunization in their countries and the global health community.

 

“Countries recently have experienced major natural disasters that resulted in outbreaks of infectious diseases. In the wake of a humanitarian crisis like the earthquake in Nepal, the international community should move fast to preemptively address potential outbreaks, such as cholera, a disease that preys on disasters,” IVI Director General Dr. Jerome Kim said. “The course provides practical knowledge and an opportunity to share experiences and to exchange views on vaccine research, development, epidemiology, and immunization among professionals from around the world especially those from developing countries.”  

 

Lectures by leading experts in vaccinology and interactive case studies will comprehensively cover disciplines and issues including epidemiology and immunobiology, vaccine discovery to process development, vaccine clinical development for licensure, vaccine licensing to introduction, introduction to use, and vaccine use and acceptance. More than 30 experts from international agencies, including IVI and the World Health Organization; research institutions, including the U.S. National Institutes of Health; universities, including London School of Hygiene and Tropical Medicine; industry, and non-profit organizations serve as faculty members.

 

As the new Director General of IVI, Dr. Kim will give a keynote speech that will touch upon current and future perspectives of HIV vaccines, his area of expertise, on May 15. Also, Dr. Sinho Jung from Samsung Medical Center will deliver a lecture on ‘Clinical Trial Design: Statistical Approach,’ and Dr. Robert Hall from the U.S. NIH, will give a talk on ‘Laboratory Diagnostics of Infectious Diseases: Current and Future Landscape,’ while Dr. Rakesh Kumar, Joint Secretary of the Ministry of Health & Family Welfare, India will lecture on ‘Addressing Challenges of Vaccine Introduction at Country Level: India.’ Ms. Melissa Malhalme from Gavi, the Vaccine Alliance will address ‘Sustainable vaccine financing: Role of Gavi in vaccine access and market shaping.’  

 

“Capacity building of developing countries is one of the three pillars of IVI’s mission along with development and delivery of vaccines for developing nations,” said Dr. Kim. “IVI will continue to provide quality training for healthcare professionals and vaccine scientists to ensure wider use of vaccines by populations in need, and seek to develop a network among participating organizations to expand partnership in vaccines, vaccination and global public health.”

 

The weeklong course is sponsored by the Korea Exchange Bank Foundation, Sky 72 Golf Club, Community Chest of Korea, Seoul Metropolitan City Government, GlaxoSmithKline (GSK), Incepta Pharmaceuticals, and Pfizer. The Swedish International Development Cooperation Agency (Sida) and the Korean Ministry of Education also has provided support.


 

 

About IVI

The International Vaccine Institute (IVI) is the world’s only international organization devoted exclusively to developing and introducing new and improved vaccines to protect the world’s poorest people, especially children in developing countries. Established in 1997, IVI operates as an independent international organization under a treaty signed by 35 countries and the World Health Organization. The Institute conducts research in more than 30 countries of Asia, Africa and Latin America on vaccines against diarrheal infections, bacterial meningitis and pneumonia, as well as Japanese encephalitis and dengue fever, and develops new and improved vaccines at its headquarters in Seoul, Republic of Korea. For more information, please visit www.ivi.int.

 

Media Contact:

 

IVI

Tae Kyung Byun

Public Awareness/Advocacy Officer, IVI

Phone: +82-2-872-2801 (Ext. 159)      

Mobile: +82-10-8773-6071

Email: tkbyun@ivi.int

 

 

DONATE